Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
Want to see BPTH full AI Analyst Report?
Top Page
Bio-Path Holdings
(OTC:BPTH)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.03
▼(-42.00% Downside)
Action:Reiterated
Date:05/14/26
The score is driven down primarily by weak financial performance (no revenue, ongoing losses/cash burn, and negative equity), followed by bearish technicals with the stock trading below all key moving averages and negative MACD. Valuation metrics provide limited support due to a negative P/E and no dividend yield data.
Positive Factors
Proprietary liposomal delivery platform (DNAbilize)
A proprietary liposomal delivery platform for RNAi therapeutics is a durable competitive asset: it can improve intracellular delivery, broaden targetability across oncology indications, and enhance partner interest. This platform-level advantage increases long-term clinical and licensing optionality.
Negative Factors
No revenue and persistent net losses
Multi-year absence of commercial revenue and recurring large net losses make the company dependent on external funding and high execution. Without approved products or licensing revenues, sustainable cash generation is uncertain and contingent on successful clinical outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary liposomal delivery platform (DNAbilize)
A proprietary liposomal delivery platform for RNAi therapeutics is a durable competitive asset: it can improve intracellular delivery, broaden targetability across oncology indications, and enhance partner interest. This platform-level advantage increases long-term clinical and licensing optionality.
Read all positive factors
Bio-Path Holdings (BPTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$326.98K
Dividend YieldN/A
Average Volume (3M)24.92K
Price to Earnings (P/E)―
Beta (1Y)-0.63
Revenue GrowthN/A
EPS Growth84.78%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding9,342,151
10 Day Avg. Volume24,655
30 Day Avg. Volume24,916
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.06
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap2.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.88
Enterprise Value/Ebitda-0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bio-Path Holdings Business Overview & Revenue Model
Company Description
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that...
How the Company Makes Money
Bio-Path Holdings does not have publicly established recurring product revenue because its drug candidates are investigational and, to the best of available public information, not approved for commercial sale. The company has historically funded ...
Bio-Path Holdings Earnings Call Summary
Earnings Call Date:Nov 15, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Positive
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.Positive Updates
Expansion of DNAbilize Platform
Initiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.
Negative Updates
Increased General and Administrative Expenses
General and administrative expenses increased to $1.3 million in Q3 2024 from $1.0 million in Q3 2023, primarily due to increased legal fees and salaries.
Read all updates
Q3-2024 Updates
Positive
Negative
Expansion of DNAbilize Platform
Initiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.
Read all positive updates
Company Guidance
In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.Bio-Path Holdings Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -96.00K | -159.00K | -178.00K | -178.00K | -161.00K |
| EBITDA | -8.24M | -9.73M | -15.76M | -13.69M | -10.28M |
| Net Income | -8.67M | -9.89M | -16.08M | -13.84M | -10.44M |
Balance Sheet | |||||
| Total Assets | 678.00K | 3.88M | 3.22M | 15.97M | 26.57M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 1.17M | 1.05M | 10.38M | 23.77M |
| Total Debt | 463.00K | 83.00K | 113.00K | 221.00K | 235.00K |
| Total Liabilities | 8.90M | 3.73M | 2.78M | 1.80M | 1.11M |
| Stockholders Equity | -8.22M | 154.00K | 441.00K | 14.17M | 25.46M |
Cash Flow | |||||
| Free Cash Flow | -1.60M | -10.57M | -11.54M | -15.12M | -9.99M |
| Operating Cash Flow | -1.60M | -10.57M | -11.54M | -15.10M | -9.92M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -21.00K | -70.00K |
| Financing Cash Flow | 423.00K | 10.70M | 2.20M | 1.73M | 20.01M |
Bio-Path Holdings Technical Analysis
Positive
0.05
Price Trends
0.06
Positive
0.06
Positive
0.09
Negative
Market Momentum
<0.01
Negative
66.69
Neutral
81.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTH, the sentiment is Positive. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.69 is Neutral, neither overbought nor oversold. The STOCH value of 81.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BPTH.
Bio-Path Holdings Risk Analysis
Bio-Path Holdings disclosed 47 risk factors in its most recent earnings report. Bio-Path Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Path Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.49M | -0.19 | -63.03% | ― | ― | 88.07% | |
44 Neutral | $1.86M | -0.20 | ― | ― | 99.48% | -474.47% | |
41 Neutral | $326.98K | -0.05 | ― | ― | ― | 84.78% | |
| ― | $2.65M | -0.27 | -168.95% | ― | ― | 84.00% |
* Healthcare Sector Average
BPTH
Bio-Path Holdings
0.04
-0.16
-82.41%
BDRX
Biodexa Pharmaceuticals
3.30
-61.20
-94.88%
QCLS
Q/C Technologies
4.33
-15.60
-78.27%
SCNI
Scinai Immunotherapeutics
0.54
-2.28
-80.99%
OGEN
Oragenics
0.59
-5.38
-90.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.